MX2021013019A - Compuestos de indol para uso en neurorestauracion. - Google Patents

Compuestos de indol para uso en neurorestauracion.

Info

Publication number
MX2021013019A
MX2021013019A MX2021013019A MX2021013019A MX2021013019A MX 2021013019 A MX2021013019 A MX 2021013019A MX 2021013019 A MX2021013019 A MX 2021013019A MX 2021013019 A MX2021013019 A MX 2021013019A MX 2021013019 A MX2021013019 A MX 2021013019A
Authority
MX
Mexico
Prior art keywords
neurorestoration
indole compounds
amyloid
indole
compounds
Prior art date
Application number
MX2021013019A
Other languages
English (en)
Inventor
Christopher G Parsons
Gerhard Rammes
Hermann Russ
Andrew L Pearlman
Original Assignee
Galimedix Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galimedix Therapeutics Inc filed Critical Galimedix Therapeutics Inc
Publication of MX2021013019A publication Critical patent/MX2021013019A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En el presente documento se proporcionan métodos de uso de compuestos derivados de indol para la reversión de la toxicidad del amiloide ß en enfermedades asociadas con el amiloide ß.
MX2021013019A 2019-04-24 2020-04-23 Compuestos de indol para uso en neurorestauracion. MX2021013019A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201962837741P 2019-04-24 2019-04-24
PCT/US2020/029455 WO2020219634A1 (en) 2019-04-24 2020-04-23 Indole compounds for use in neurorestoration

Publications (1)

Publication Number Publication Date
MX2021013019A true MX2021013019A (es) 2022-01-18

Family

ID=70847482

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013019A MX2021013019A (es) 2019-04-24 2020-04-23 Compuestos de indol para uso en neurorestauracion.

Country Status (8)

Country Link
US (1) US20220193035A1 (es)
EP (1) EP3958864A1 (es)
JP (1) JP2022529742A (es)
CN (1) CN114072146A (es)
BR (1) BR112021021267A2 (es)
IL (1) IL287508A (es)
MX (1) MX2021013019A (es)
WO (1) WO2020219634A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023214317A1 (en) * 2022-05-04 2023-11-09 Galimedix Therapeutics Inc. Relative undersupply of an amyloid beta aggregation inhibitor for improved detoxifying effects

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2044951A1 (en) * 2007-10-02 2009-04-08 Merz Pharma GmbH & Co. KGaA The use of substances for the treatment of loss of eyesight in humans with glaucoma and other degenerative eye diseases
CA2805968A1 (en) * 2010-07-22 2012-01-26 Merz Pharma Gmbh & Co. Kgaa Pharmaceutical composition containing a tryptophan derivative
RU2013124827A (ru) * 2010-10-29 2014-12-10 Мерц Фарма Гмбх Унд Ко. Кгаа Производные индола и способ их получения
EP3431489B1 (en) 2010-11-15 2020-12-23 Ramot at Tel-Aviv University Ltd. Dipeptide analogs for treating conditions associated with amyloid fibril formation
WO2013018960A1 (ko) 2011-08-02 2013-02-07 부경대학교 산학협력단 전처리된 해조류 잔사의 추출물을 이용한 휘발성 지방산 제조 방법
TW201412325A (zh) * 2012-06-20 2014-04-01 梅茲製藥有限兩合公司 用於治療患有青光眼及其他退化性眼疾之人類視力喪失的間隔醫療

Also Published As

Publication number Publication date
WO2020219634A1 (en) 2020-10-29
JP2022529742A (ja) 2022-06-23
IL287508A (en) 2021-12-01
US20220193035A1 (en) 2022-06-23
CN114072146A (zh) 2022-02-18
EP3958864A1 (en) 2022-03-02
BR112021021267A2 (pt) 2021-12-21

Similar Documents

Publication Publication Date Title
CL2021000972A1 (es) Inhibidores de la proteína tirosina fosfatasa
CO2020000527A2 (es) Compuestos y composiciones para tratar afecciones asociadas con la actividad nlrp
CY1124959T1 (el) Αναστολεις λυσινης ειδικης απομεθυλασης-1
EA201790078A1 (ru) Ингибиторы mnk и связанные с ними способы
CY1124789T1 (el) Πυριμιδιν-2-υλαμινο-1η-πυραζολια ως αναστολεις lrrk2 για χρηση στη θεραπεια νευροεκφυλιστικων διαταραχων
EA201890307A1 (ru) Индазольные и азаиндазольные соединения как ингибиторы irak-4
EA201992235A1 (ru) Синтез ингибитора mcl-1
EP4006016A3 (en) Probes for imaging huntingtin protein
EA201791289A1 (ru) Ингибиторы клеточного некроза и связанные с ними способы
MX2017006165A (es) Derivados heterociclicos y uso de los mismos.
MX2021005891A (es) Sondas para la proyeccion de imagen de la proteina huntingtina.
EA201791945A1 (ru) Пирролидинкарбоксамидопроизводные и способы их получения и их применение
WO2019178487A3 (en) Compositions and methods for treating disease using klebsiella quasipneumoniae subsp. similipneumoniae
EA201790046A1 (ru) Бензоксазиноновые амиды в качестве модуляторов минералокортикоидного рецептора
EA201790156A1 (ru) Азетидинилоксифенилпирролидиновые соединения
CL2021002108A1 (es) Desinfectante endoscopico mejorado
CR20190344A (es) Activador de nrf2
MX2021003643A (es) Derivados de terpenoides y usos de los mismos.
EA201892311A1 (ru) Производные 2-анилинопиримидина в качестве терапевтических агентов для лечения рака мозга
MX2021013019A (es) Compuestos de indol para uso en neurorestauracion.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
EA201990313A1 (ru) Производное триазолопиразинона, пригодное в качестве ингибитора фдэ1 человека
MX2018008895A (es) Compuestos de 2-oxindol.
MY180727A (en) Tetrahydrofurane-fused aminohydrothiazine derivatives which are useful in the treatment of alzeimer?s disease
WO2018211324A8 (en) Prodrugs for the treatment of disease